CR8403A - Formas de dosificacion farmaceutica de liberacion extendida - Google Patents

Formas de dosificacion farmaceutica de liberacion extendida

Info

Publication number
CR8403A
CR8403A CR8403A CR8403A CR8403A CR 8403 A CR8403 A CR 8403A CR 8403 A CR8403 A CR 8403A CR 8403 A CR8403 A CR 8403A CR 8403 A CR8403 A CR 8403A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical dosage
extended
liberation
dosage forms
mammals
Prior art date
Application number
CR8403A
Other languages
English (en)
Inventor
Heaton Nicholas
Potts Angela
Armstrong Ian
Andrew Provost James
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34354596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8403(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8403A publication Critical patent/CR8403A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invenion se relaciona con formas novedosas de dosificacion farmaceutica de liberacion extendida para drogas oralmente suministradas a mamiferos, por ejemplo humanos.
CR8403A 2003-10-13 2006-05-12 Formas de dosificacion farmaceutica de liberacion extendida CR8403A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03256438A EP1523979A1 (en) 2003-10-13 2003-10-13 Extended release pharmaceutical dosage form

Publications (1)

Publication Number Publication Date
CR8403A true CR8403A (es) 2006-10-26

Family

ID=34354596

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8403A CR8403A (es) 2003-10-13 2006-05-12 Formas de dosificacion farmaceutica de liberacion extendida

Country Status (14)

Country Link
US (1) US20050129762A1 (es)
EP (2) EP1523979A1 (es)
KR (1) KR20060108675A (es)
CN (1) CN1889935A (es)
AR (1) AR046102A1 (es)
AU (1) AU2004283436A1 (es)
CA (1) CA2546199A1 (es)
CO (1) CO5690532A2 (es)
CR (1) CR8403A (es)
EC (1) ECSP066566A (es)
NO (1) NO20062142L (es)
PE (1) PE20050439A1 (es)
TW (1) TW200518788A (es)
WO (1) WO2005039527A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
AU2005320547B2 (en) * 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
AU2007335156A1 (en) * 2006-12-20 2008-06-26 Mylan Pharmaceuticals Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
AU2014201170B2 (en) * 2006-12-20 2015-09-24 Mylan Pharmaceuticals Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
CA2681174C (en) 2007-03-22 2020-06-02 Guosong Liu Magnesium compositions and uses thereof
US8178132B2 (en) 2007-03-22 2012-05-15 Magceutics, Inc. Magnesium-containing food compositions
WO2011003045A1 (en) 2009-07-01 2011-01-06 Magceutics, Inc. Slow release magnesium composition and uses thereof
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556141A (es) * 1956-03-27
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US20030059466A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Delayed release tablet of venlafaxin
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
AU2003226752A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Venlafaxine base
IL149055A0 (en) * 2002-04-09 2002-11-10 Karma Pharm Ltd Extended release composition comprising as active compound venlafaxine hydrochloride
CA2536111A1 (en) * 2003-07-24 2005-02-03 Wockhardt Limited Oral compositions for treatment of diseases

Also Published As

Publication number Publication date
AR046102A1 (es) 2005-11-23
CN1889935A (zh) 2007-01-03
WO2005039527A2 (en) 2005-05-06
WO2005039527A3 (en) 2006-04-06
ECSP066566A (es) 2006-10-17
CA2546199A1 (en) 2005-05-06
AU2004283436A1 (en) 2005-05-06
TW200518788A (en) 2005-06-16
NO20062142L (no) 2006-07-06
PE20050439A1 (es) 2005-08-03
CO5690532A2 (es) 2006-10-31
EP1523979A1 (en) 2005-04-20
EP1675575A2 (en) 2006-07-05
US20050129762A1 (en) 2005-06-16
KR20060108675A (ko) 2006-10-18

Similar Documents

Publication Publication Date Title
CR8403A (es) Formas de dosificacion farmaceutica de liberacion extendida
CL2004001119A1 (es) Compuestos derivados de oximas; composiciones farmaceutica que los contienen; y su uso como inmunosupresores utiles en enfermedades mediadas por el receptor edg, talees como enfermedades autoinmunes, inflamatorias, infecciosas y cancer.
UY30712A1 (es) Nuevos derivados de 1, 4-benzotiepina-1, 1-dioxido sustituidos con fluor, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
UY29983A1 (es) Derivados de 4-amino-pirrolotriazina sustituida utiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogenesis
UY30710A1 (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales ciclohexilo, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
CR9772A (es) Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos
CL2004001120A1 (es) Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
BRPI0606339A2 (pt) formas farmacêuticas resistentes a álcool
SV2006002201A (es) Polimorfo ii de rapamicina y sus utilizaciones ref. am- 101733salvo
GT200600500A (es) Composición farmacéutica orodispersable para la administración oromucosal o sublingual de la agomelatina
CY1111977T1 (el) Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
HN2008001191A (es) Compuestos de biciclolactama sustituida
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
ATE528989T1 (de) Kristalline feste rasagilin-base
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
CY1116759T1 (el) Ανθελονοσιακη φαρμακευτικη συνθεση
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
CL2008001728A1 (es) Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CO5690567A2 (es) Formulaciones de tableta de liberacion extendida de venlafaxina
UY27275A1 (es) Composiciones y metodos para aumentar la biodisponibilidad de agentes farmacéuticos
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением